title: sHLA-G levels in the monitoring of immunosuppressive therapy and rejection following heart transplantation.
abstract: The aim of this study was to further determine the immediate influence, over a 12-h period, after the initiation of daily immunosuppressive treatment on the serum levels of sHLA-G in heart transplant patients during the post-transplant period (1 month). It was found that there are two patterns of patients in term of the changes observed in their levels of sHLA-G in response to the immunosuppressive treatment. One group (group A) showed no changes on sHLA-G while the other group (group B) a significant rise in sHLA-G levels was observed at 2 to 4 h post dose. Interestingly, it was observed that the patients in group B have better prognosis of acceptance of the heart graft than those of group A. On the other hand it was found that the patients with high levels of sHLA-G (77.3+/-34.8 ng/ml) in pre-transplant sera have a better prognosis of acceptance of the heart graft than those with low sHLA-G levels (9.7+/-7.1 ng/ml). In conclusion, both the intensity of changes of sHLA-G levels induced by immunosuppression and basal levels in pre-transplant could be used in the monitoring of the immunosuppression as well as the heart transplant evolution.
authors.affiliation: Service of Immunology, Reina Sofía University Hospital, Cordoba, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Luque
authors.forename: M I
authors.initials: MI
authors.lastname: Torres
authors.forename: M D
authors.initials: MD
authors.lastname: Aumente
authors.forename: J M
authors.initials: JM
authors.lastname: Lozano
authors.forename: G
authors.initials: G
authors.lastname: García-Jurado
authors.forename: R
authors.initials: R
authors.lastname: González
authors.forename: M R
authors.initials: MR
authors.lastname: Alvarez-López
authors.forename: J M
authors.initials: JM
authors.lastname: Arizón
authors.forename: J
authors.initials: J
authors.lastname: Peña
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D005260:Female; D006084:Graft Rejection / Q000209:etiology* / Q000276:immunology*; D006680:HLA Antigens / Q000097:blood*; D059951:HLA-G Antigens; D016027:Heart Transplantation / Q000009:adverse effects* / Q000276:immunology*; D015395:Histocompatibility Antigens Class I / Q000097:blood*; D006801:Humans; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012995:Solubility; D023001:Transplantation Tolerance
chemical_list: D006680:HLA Antigens; D059951:HLA-G Antigens; D015395:Histocompatibility Antigens Class I; D007166:Immunosuppressive Agents